Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA warning letter adds to Wockhardt's GMP woes

This article was originally published in Scrip

Executive Summary

The US FDA's latest warning letter against two of Wockhardt's Indian manufacturing sites has reiterated serious concerns about the integrity of data generated by the firm, which some analysts believe casts a deep shadow over resolution timelines given the unclear scope of current good manufacturing practice (cGMP) violations under scrutiny.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023675

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel